live sessions
PDT:
Pacific Daylight Time
PDT:
Pacific Daylight Time
All Sessions
Live Now:
MAR9
8:30 AMto12:30 PMPDT
12:00 PMto5:00 PMPDT
Scott M. Hammer Workshop for New Investigators and Trainees
8:30 AM8:30 AM
Welcome and (Session Overview) for the Scott M. Hammer Workshop for New Investigators and Trainees
8:31 AM8:31 AM
Virology: State of the Art and Navigating Presentations at CROI 2025
Stuart J.D. Neil
King's College London, London, UK
9:10 AM9:10 AM
Immunology: State of the Art and Navigating Presentations at CROI 2025
Lishomwa Ndhlovu
Weill Cornell Medicine, New York, NY, USA
10:10 AM10:10 AM
Prevention of HIV and STIs: State of the Art and Navigating Presentations at CROI 2025
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
10:50 AM10:50 AM
HIV Treatment and Complications of HIV Disease: State of the Art and Navigating Presentations at CROI 2025
Judith S. Currier
University of California Los Angeles, Los Angeles, CA, USA
11:50 AM11:50 AM
HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025
Joseph J. Eron, Jr
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
12:20 PM12:20 PM
Message to New Investigators
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Frontiers in Laboratory Technologies
2:00 PM2:00 PM
2 - Breaking the HIV Capsid: Atomic Force Microscopy Visualization
Juan R. Perilla
University of Delaware, Newark, DE, USA
2:30 PM2:30 PM
3 - Advances in Single-Cell Multiomic Profiling and Its Use in Virology and Immunology
Alexander Marson
University of California San Francisco, San Francisco, CA, USA
3:00 PM3:00 PM
4 - Visualizing Tissues: State-of-the-Art Single-Cell 3D Spatial Transcriptomics
Nikolaus Rajewsky
Berlin Institute for Medical Systems Biology, Berlin, Germany
3:30 PM3:30 PM
5 - Advances in CRISPR-Cas Editing Methods and Their Use in Virology and Immunology
Angela R. Wahl
University of Alabama at Birmingham, Birmingham, AL, USA
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Case-Based Workshop on the Liver and Its Complications
2:00 PM2:00 PM
6 - Liver Steatosis: New Nomenclature, New Tests, and New Drugs
Mandana Khalili
University of California San Francisco, San Francisco, CA, USA
2:40 PM2:40 PM
7 - Hepatitis B in the Gray Zone: Personalizing Treatment and Monitoring
Paul Y. Kwo
Stanford University, Stanford, CA, USA
3:20 PM3:20 PM
8 - Liver Cancer Surveillance: Who, How, When, and For How Long
Fasiha Kanwal
Baylor College of Medicine, Houston, TX, USA
3:50 PM3:50 PM
Discussion with Audience Questions and Answers
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Clinical Trial Design and Analysis
2:00 PM2:00 PM
9 - Using Machine Learning to Focus HIV Prevention Interventions
Carlos S. Saldana
Emory University, Atlanta, GA, USA
2:40 PM2:40 PM
10 - HIV Prevention Efficacy Trial Design: Lessons From Recent Trials
Holly Janes
Fred Hutchinson Cancer Center, Seattle, WA, USA
3:20 PM3:20 PM
11 - How Much Is Enough: The Importance of Pharmacokinetic Targets
Paolo Denti
University of Cape Town, Cape Town, South Africa
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Workshop on Antiretroviral Therapy: Case-Based Panel Discussion
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Jose R. Arribas
Hospital La Paz Institute for Health Research, Madrid, Spain
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, USA
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Cecilia Kanyama
UNC Project, Lilongwe. Malawi
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Juan Sierra-Madero
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Oana Sandulescu
Carol Davila University of Medicine and Pharmacy, București, Romania
5:00 PM5:00 PM
Welcome from the Conference Chair
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
5:10 PM5:10 PM
Introduction to the Bernard Fields Lecture
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, USA
5:15 PM5:15 PM
13 - Bernard Fields Lecture: How Integration Site Analyses Inform HIV Pathogenesis, Persistence, and Gene Therapy
Frederic D. Bushman
University of Pennsylvania, Philadelphia, PA, USA
5:40 PM5:40 PM
Introduction to the Martin Delaney Presentation
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
5:45 PM5:45 PM
14 - Martin Delaney Presentation: 40+ Years of HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must
Rebecca Denison
Woman Organized to Respond to Life-threatening Diseases (WORLD), Berkeley, CA, USA
6:10 PM6:10 PM
Introduction to the N'Galy-Mann Lecture
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
6:15 PM6:15 PM
15 - N'Galy-Mann Lecture: When Science Alone is Not Enough: The Intersection of Drug Use, Public Health, and Policy
Adeeba Kamarulzaman
Monash University Malaysia, Kuala Lumpur, Malaysia
6:40 PM6:40 PM
Special Presentation by the San Francisco Gay Men's Chorus
6:59 PM6:59 PM
Opening Session Conclusion and Welcome to the Opening Reception
Nicolas Chomont
Université de Montréal, Montreal, Canada
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
16 - HIV Cure: A Translational Research Perspective
Ole Søgaard
Aarhus University, Aarhus, Denmark
9:05 AM9:05 AM
17 - The Global HIV/AIDS Pandemic: Where Are We Now?
Chris Beyrer
Duke Global Health Institute, Durham, NC, USA
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Deciphering the Mystery of Viral Rebound
4:00 PM4:00 PM
18 - Utilizing a Barcoded Virus Model to Identify the Source of Viral Rebound
Brandon Keele
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
4:20 PM4:20 PM
19 - Cellular and Tissue Sources of Viral Persistence and Rebound
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
4:40 PM4:40 PM
20 - Immune Responses During Viral Rebound
Rachel Rutishauser
University of California San Francisco, San Francisco, CA, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Filling the Gaps: Challenges and Opportunities in the Care of Children and Youth With Perinatal HIV
4:00 PM4:00 PM
21 - Advanced HIV Disease in Children
Pablo Rojo
Hospital Universitario 12 de Octubre, Madrid, Spain
4:20 PM4:20 PM
22 - HIV Care Continuum in Children
Irene Njuguna
University of Washington, Seattle, WA, USA
4:40 PM4:40 PM
23 - Sexual, Reproductive, and Pregnancy Health Among People With Perinatal HIV
Caroline Foster
Imperial College Healthcare NHS Trust, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Closing the Gaps in the HIV Response
4:00 PM4:00 PM
24 - Immediate Challenges and Long-Term Goals of the HIV Response
Jeffrey Imai-Eaton
Harvard TH Chan School of Public Health
4:20 PM4:20 PM
25 - Integration and Sustainability of the Global HIV Response
Tsitsi Apollo
Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe
4:40 PM4:40 PM
26 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind
Izukanji Sikazwe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestMiddleName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestMiddleName 4 TestLastName 4
Institution 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
8:35 AM8:35 AM
27 - HIV Acquisition and Prevention During Pregnancy and Postpartum
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
9:05 AM9:05 AM
28 - Systems Vaccinology
Bali Pulendran
Stanford University, Stanford, CA, USA
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Breaking In and Setting Up Home: From HIV Nuclear Entry and Integration to Viral Gene Expression and Establishing the Reservoir
4:00 PM4:00 PM
29 - How HIV Capsid Breaches the Nuclear Envelope Through Karyopherin Mimicry
David Jacques
University of New South Wales, Sydney, Australia
4:18 PM4:18 PM
30 - How HIV Integrates Into the Genome
Alan N Engelman
Dana–Farber Cancer Institute, Boston, MA, USA
4:36 PM4:36 PM
31 - Transcriptional and Epigenetic Regulation of HIV-1 Gene Expression
Melanie Ott
Gladstone Institutes, San Francisco, CA, USA
4:54 PM4:54 PM
32 - The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation
Mary Kearney
National Cancer Institute at Frederick, Frederick, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
4:00 PM4:00 PM
33 - Beyond Hot Flashes: Women's Lived Experience of Menopause
Bridgette Picou
The Well Project: Women's Research Initiative on HIV/AIDS, Brooklyn, NY, USA
4:10 PM4:10 PM
34 - Clinical Management of Women With HIV in Menopause
Sara Looby
Massachusetts General Hospital, Boston, MA, USA
4:25 PM4:25 PM
35 - Influence of Hormone Changes on Physiology, Virology, and Immunology
Eileen Scully
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
5:00 PM5:00 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Long-Acting Preexposure Prophylaxis for HIV Prevention
4:00 PM4:00 PM
38 - Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention
Jonathan Li
Brigham and Women's Hospital, Boston, MA, USA
4:20 PM4:20 PM
39 - Complexities of HIV Diagnosis: What Lies Beneath
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
4:40 PM4:40 PM
40 - Long-Acting Preexposure Prophylaxis: Why Can’t We Get to Scale?
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
5:00 PM5:00 PM
36 - Long-Acting Treatments for Tuberculosis
Eric Nuermberger
The Johns Hopkins University, Baltimore, MD, USA
5:20 PM5:20 PM
37 - Post-Tuberculosis Disease: Opening Pandora's Box
Brian Allwood
Stellenbosch University, Cape Town, South Africa
6:00 PM6:00 PM
Discussion with Audience Questions and Answers
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
41 - Long COVID: Causes, Consequences, and the Way Forward
Roger Paredes
IrsiCaixa, Badalona, Spain
9:05 AM9:05 AM
42 - Weight Gain in People With HIV
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
167 - Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection
Robert Paul
University of Missouri St Louis, St Louis, MO, USA
10:13 AM10:13 AM
168 - Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
10:21 AM10:21 AM
169 - Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART
Joshua C. Cyktor
University of Pittsburgh, Pittsburgh, PA, USA
10:29 AM10:29 AM
170 - Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART
Shelli Farhadian
Yale University, New Haven, CT, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
171 - Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
11:08 AM11:08 AM
172 - Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
11:16 AM11:16 AM
173 - Brain Gray and White Matter Alterations in Cognitive Long COVID
Lindsay S. McAlpine
Yale University, New Haven, CT, USA
11:24 AM11:24 AM
174 - Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV
Jacob Bolzenius
University of Missouri St Louis, St Louis, MO, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Cardiometabolic Complications and Aging: The Clock Is Ticking
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
175 - Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study
Alejandro Garcia
Hospital Ramón y Cajal, Madrid, Spain
10:13 AM10:13 AM
176 - Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study
Nila J. Dharan
University of New South Wales Sydney, Sydney, Australia
10:21 AM10:21 AM
177 - Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda
Mark J. Siedner
Massachusetts General Hospital, Boston, MA, USA
10:29 AM10:29 AM
178 - Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
179 - Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11:08 AM11:08 AM
180 - Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection
Patricia Martínez-Martín
La Paz University Hospital, Madrid, Spain
11:16 AM11:16 AM
181 - Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy
Michael J. Corley
Weill Cornell Medicine, New York, NY, USA
11:24 AM11:24 AM
182 - Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
Sara Gianella Weibel
University of California San Diego, La Jolla, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Gaps and Solutions in the HIV Response
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
183 - Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Steve Shoptaw
University of California Los Angeles, Los Angeles, CA, USA
10:13 AM10:13 AM
184 - Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda
Silas Odiya
Rakai Health Sciences Program, Kalisizo, Uganda
10:21 AM10:21 AM
185 - Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Kathryn L. Dovel
University of California Los Angeles, Los Angeles, CA, USA
10:29 AM10:29 AM
186 - Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study
Joseph G. Rosen
Brown University, Providence, RI, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
187 - How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?
Solis Winters
University of California Berkeley, Berkeley, CA, USA
11:08 AM11:08 AM
188 - Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia
Aaloke Mody
Washington University in St Louis, St Louis, MO, USA
11:16 AM11:16 AM
189 - Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV
Sarah Gimbel
University of Washington, Seattle, WA, USA
11:24 AM11:24 AM
190 - SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Expanding the Prevention Toolbox
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
191 - Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
10:13 AM10:13 AM
192 - ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
10:21 AM10:21 AM
193 - Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
194 - Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
195 - Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
11:08 AM11:08 AM
196 - PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Taimur Khan
Fenway Health, Boston, MA, USA
11:16 AM11:16 AM
197 - Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
11:32 AM11:32 AM
199 - An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR12
12:15 PMto1:15 PMPDT
12:00 PMto5:00 PMPDT
Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!
12:15 PM12:15 PM
(Introduction of Speakers)
12:15 PM12:15 PM
200 - Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results
Frederick G. Hayden
University of Virginia, Charlottesville, VA, USA
12:23 PM12:23 PM
201 - Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
Timothy Wilkin
University of California San Diego, La Jolla, CA, USA
12:31 PM12:31 PM
202 - Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
12:39 PM12:39 PM
203 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Babafemi Taiwo
ViiV Healthcare, Durham, NC, USA
12:47 PM12:47 PM
204A - Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1
Amy E. Colson
Community Resource Initiative, Boston, MA, USA
12:55 PM12:55 PM
204B - Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1
Chloe Orkin
Queen Mary University of London, London, UK
12:59 PM12:59 PM
Questions and Answers
1:30 PM1:30 PM
(Session Overview)
Zabrina L. Brumme
Simon Fraser University, Burnaby, Canada
1:35 PM1:35 PM
585 - HIV Reservoir in Jejunum Exhibit Distinct Phenotypic Features and Evoke Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
1:40 PM1:40 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
1:45 PM1:45 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
1:50 PM1:50 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:55 PM1:55 PM
Discussion with Audience Q&A
1:30 PM1:30 PM
(Session Overview)
Ceri Evans
University of Liverpool, Liverpool, United Kingdom
1:35 PM1:35 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
1:40 PM1:40 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
1:45 PM1:45 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
1:50 PM1:50 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Long COVID: Pathogenesis and Clinical Manifestations
1:30 PM1:30 PM
(Session Overview)
1:35 PM1:35 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:40 PM1:40 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
1:45 PM1:45 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:50 PM1:50 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
1:55 PM1:55 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Lessons in DoxyPEP Implementation
1:30 PM1:30 PM
(Session Overview)
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
1:35 PM1:35 PM
1275 - Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Jesús Santos
Hospital Universitario Virgen de la Victoria, Málaga, Spain
1:40 PM1:40 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
1:45 PM1:45 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Post-Exposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
1:50 PM1:50 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Pathogenesis of HIV in the Brain: The Final Frontier
4:00 PM4:00 PM
43 - Multiomics in the Brain
Howard Fox
University of Nebraska, Omaha, NE, USA
4:20 PM4:20 PM
44 - The Central Nervous System Reservoir: Impact for Cure and Ongoing Neuropathology
Melissa Churchill
Royal Melbourne Institute of Technology, Melbourne, Australia
4:40 PM4:40 PM
45 - Emerging Role of T Cells in the Central Nervous System
Lydie Trautmann
Henry M Jackson Foundation, Bethesda, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Making Sense of Integrase Strand Transfer Inhibitor Failure and Resistance
4:00 PM4:00 PM
46 - Dolutegravir Resistance: How Frequent Is It and How Will It Evolve?
Nicaise Ndembi
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
4:20 PM4:20 PM
47 - Dolutegravir Resistance: What Are the Implications for Antiretroviral Therapy Programs?
Jeremy Nel
University of Witwatersrand, Johannesburg, South Africa
4:40 PM4:40 PM
48 - Long-Acting InSTI Strategies: Understanding the Risks for Failure and Resistance
Saye Khoo
University of Liverpool, Liverpool, UK
5:00 PM5:00 PM
Panel Discussion
Brenda E. Crabtree Ramírez
National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Mexico
5:00 PM5:00 PM
Panel Discussion
Suzanne McCluskey
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Panel Discussion
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Putting People at the Center of Prevention: New Models of Delivery
4:00 PM4:00 PM
49 - Leveraging Private-Sector Pharmacies to Expand Reach of Biomedical HIV Prevention Interventions
Katrina Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
4:20 PM4:20 PM
50 - Empowering Communities: A Peer-Based Model for Expanding Equitable Access to PrEP and PEP in Mexico
Alaín Pinzón
Vihve Libre, Mexico City, Mexico
4:40 PM4:40 PM
51 - We’ll Come to You: A Mobile Clinic Preexposure Prophylaxis Delivery Model
Elzette Rousseau
Desmond Tutu HIV Foundation, Cape Town, South Africa
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
Upcoming:
MAR9
8:30 AMto12:30 PMPDT
12:00 PMto5:00 PMPDT
Scott M. Hammer Workshop for New Investigators and Trainees
8:30 AM8:30 AM
Welcome and (Session Overview) for the Scott M. Hammer Workshop for New Investigators and Trainees
8:31 AM8:31 AM
Virology: State of the Art and Navigating Presentations at CROI 2025
Stuart J.D. Neil
King's College London, London, UK
9:10 AM9:10 AM
Immunology: State of the Art and Navigating Presentations at CROI 2025
Lishomwa Ndhlovu
Weill Cornell Medicine, New York, NY, USA
10:10 AM10:10 AM
Prevention of HIV and STIs: State of the Art and Navigating Presentations at CROI 2025
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
10:50 AM10:50 AM
HIV Treatment and Complications of HIV Disease: State of the Art and Navigating Presentations at CROI 2025
Judith S. Currier
University of California Los Angeles, Los Angeles, CA, USA
11:50 AM11:50 AM
HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025
Joseph J. Eron, Jr
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
12:20 PM12:20 PM
Message to New Investigators
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Frontiers in Laboratory Technologies
2:00 PM2:00 PM
2 - Breaking the HIV Capsid: Atomic Force Microscopy Visualization
Juan R. Perilla
University of Delaware, Newark, DE, USA
2:30 PM2:30 PM
3 - Advances in Single-Cell Multiomic Profiling and Its Use in Virology and Immunology
Alexander Marson
University of California San Francisco, San Francisco, CA, USA
3:00 PM3:00 PM
4 - Visualizing Tissues: State-of-the-Art Single-Cell 3D Spatial Transcriptomics
Nikolaus Rajewsky
Berlin Institute for Medical Systems Biology, Berlin, Germany
3:30 PM3:30 PM
5 - Advances in CRISPR-Cas Editing Methods and Their Use in Virology and Immunology
Angela R. Wahl
University of Alabama at Birmingham, Birmingham, AL, USA
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Case-Based Workshop on the Liver and Its Complications
2:00 PM2:00 PM
6 - Liver Steatosis: New Nomenclature, New Tests, and New Drugs
Mandana Khalili
University of California San Francisco, San Francisco, CA, USA
2:40 PM2:40 PM
7 - Hepatitis B in the Gray Zone: Personalizing Treatment and Monitoring
Paul Y. Kwo
Stanford University, Stanford, CA, USA
3:20 PM3:20 PM
8 - Liver Cancer Surveillance: Who, How, When, and For How Long
Fasiha Kanwal
Baylor College of Medicine, Houston, TX, USA
3:50 PM3:50 PM
Discussion with Audience Questions and Answers
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Clinical Trial Design and Analysis
2:00 PM2:00 PM
9 - Using Machine Learning to Focus HIV Prevention Interventions
Carlos S. Saldana
Emory University, Atlanta, GA, USA
2:40 PM2:40 PM
10 - HIV Prevention Efficacy Trial Design: Lessons From Recent Trials
Holly Janes
Fred Hutchinson Cancer Center, Seattle, WA, USA
3:20 PM3:20 PM
11 - How Much Is Enough: The Importance of Pharmacokinetic Targets
Paolo Denti
University of Cape Town, Cape Town, South Africa
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Workshop on Antiretroviral Therapy: Case-Based Panel Discussion
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Jose R. Arribas
Hospital La Paz Institute for Health Research, Madrid, Spain
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, USA
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Cecilia Kanyama
UNC Project, Lilongwe. Malawi
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Juan Sierra-Madero
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Oana Sandulescu
Carol Davila University of Medicine and Pharmacy, București, Romania
MAR9
5:00 PMto7:00 PMPDT
12:00 PMto5:00 PMPDT
Opening Session
5:00 PM5:00 PM
Welcome from the Conference Chair
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
5:10 PM5:10 PM
Introduction to the Bernard Fields Lecture
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, USA
5:15 PM5:15 PM
13 - Bernard Fields Lecture: How Integration Site Analyses Inform HIV Pathogenesis, Persistence, and Gene Therapy
Frederic D. Bushman
University of Pennsylvania, Philadelphia, PA, USA
5:40 PM5:40 PM
Introduction to the Martin Delaney Presentation
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
5:45 PM5:45 PM
14 - Martin Delaney Presentation: 40+ Years of HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must
Rebecca Denison
Woman Organized to Respond to Life-threatening Diseases (WORLD), Berkeley, CA, USA
6:10 PM6:10 PM
Introduction to the N'Galy-Mann Lecture
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
6:15 PM6:15 PM
15 - N'Galy-Mann Lecture: When Science Alone is Not Enough: The Intersection of Drug Use, Public Health, and Policy
Adeeba Kamarulzaman
Monash University Malaysia, Kuala Lumpur, Malaysia
6:40 PM6:40 PM
Special Presentation by the San Francisco Gay Men's Chorus
6:59 PM6:59 PM
Opening Session Conclusion and Welcome to the Opening Reception
Nicolas Chomont
Université de Montréal, Montreal, Canada
MAR9
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
MAR9
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
MAR10
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
16 - HIV Cure: A Translational Research Perspective
Ole Søgaard
Aarhus University, Aarhus, Denmark
9:05 AM9:05 AM
17 - The Global HIV/AIDS Pandemic: Where Are We Now?
Chris Beyrer
Duke Global Health Institute, Durham, NC, USA
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
HIV Self-Testing: Here and Now
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Deciphering the Mystery of Viral Rebound
4:00 PM4:00 PM
18 - Utilizing a Barcoded Virus Model to Identify the Source of Viral Rebound
Brandon Keele
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
4:20 PM4:20 PM
19 - Cellular and Tissue Sources of Viral Persistence and Rebound
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
4:40 PM4:40 PM
20 - Immune Responses During Viral Rebound
Rachel Rutishauser
University of California San Francisco, San Francisco, CA, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Filling the Gaps: Challenges and Opportunities in the Care of Children and Youth With Perinatal HIV
4:00 PM4:00 PM
21 - Advanced HIV Disease in Children
Pablo Rojo
Hospital Universitario 12 de Octubre, Madrid, Spain
4:20 PM4:20 PM
22 - HIV Care Continuum in Children
Irene Njuguna
University of Washington, Seattle, WA, USA
4:40 PM4:40 PM
23 - Sexual, Reproductive, and Pregnancy Health Among People With Perinatal HIV
Caroline Foster
Imperial College Healthcare NHS Trust, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Closing the Gaps in the HIV Response
4:00 PM4:00 PM
24 - Immediate Challenges and Long-Term Goals of the HIV Response
Jeffrey Imai-Eaton
Harvard TH Chan School of Public Health
4:20 PM4:20 PM
25 - Integration and Sustainability of the Global HIV Response
Tsitsi Apollo
Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe
4:40 PM4:40 PM
26 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind
Izukanji Sikazwe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestMiddleName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestMiddleName 4 TestLastName 4
Institution 4
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
MAR11
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
8:35 AM8:35 AM
27 - HIV Acquisition and Prevention During Pregnancy and Postpartum
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
9:05 AM9:05 AM
28 - Systems Vaccinology
Bali Pulendran
Stanford University, Stanford, CA, USA
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Natural-Born Killers
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Breaking In and Setting Up Home: From HIV Nuclear Entry and Integration to Viral Gene Expression and Establishing the Reservoir
4:00 PM4:00 PM
29 - How HIV Capsid Breaches the Nuclear Envelope Through Karyopherin Mimicry
David Jacques
University of New South Wales, Sydney, Australia
4:18 PM4:18 PM
30 - How HIV Integrates Into the Genome
Alan N Engelman
Dana–Farber Cancer Institute, Boston, MA, USA
4:36 PM4:36 PM
31 - Transcriptional and Epigenetic Regulation of HIV-1 Gene Expression
Melanie Ott
Gladstone Institutes, San Francisco, CA, USA
4:54 PM4:54 PM
32 - The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation
Mary Kearney
National Cancer Institute at Frederick, Frederick, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:00 PMPDT
12:00 PMto5:00 PMPDT
Hot Topic: Menopause and HIV
4:00 PM4:00 PM
33 - Beyond Hot Flashes: Women's Lived Experience of Menopause
Bridgette Picou
The Well Project: Women's Research Initiative on HIV/AIDS, Brooklyn, NY, USA
4:10 PM4:10 PM
34 - Clinical Management of Women With HIV in Menopause
Sara Looby
Massachusetts General Hospital, Boston, MA, USA
4:25 PM4:25 PM
35 - Influence of Hormone Changes on Physiology, Virology, and Immunology
Eileen Scully
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
5:00 PM5:00 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Long-Acting Preexposure Prophylaxis for HIV Prevention
4:00 PM4:00 PM
38 - Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention
Jonathan Li
Brigham and Women's Hospital, Boston, MA, USA
4:20 PM4:20 PM
39 - Complexities of HIV Diagnosis: What Lies Beneath
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
4:40 PM4:40 PM
40 - Long-Acting Preexposure Prophylaxis: Why Can’t We Get to Scale?
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
5:00 PMto6:00 PMPDT
12:00 PMto5:00 PMPDT
Tuberculosis: The Long Game
5:00 PM5:00 PM
36 - Long-Acting Treatments for Tuberculosis
Eric Nuermberger
The Johns Hopkins University, Baltimore, MD, USA
5:20 PM5:20 PM
37 - Post-Tuberculosis Disease: Opening Pandora's Box
Brian Allwood
Stellenbosch University, Cape Town, South Africa
6:00 PM6:00 PM
Discussion with Audience Questions and Answers
MAR11
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
MAR12
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Wednesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
41 - Long COVID: Causes, Consequences, and the Way Forward
Roger Paredes
IrsiCaixa, Badalona, Spain
9:05 AM9:05 AM
42 - Weight Gain in People With HIV
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
167 - Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection
Robert Paul
University of Missouri St Louis, St Louis, MO, USA
10:13 AM10:13 AM
168 - Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
10:21 AM10:21 AM
169 - Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART
Joshua C. Cyktor
University of Pittsburgh, Pittsburgh, PA, USA
10:29 AM10:29 AM
170 - Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART
Shelli Farhadian
Yale University, New Haven, CT, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
171 - Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
11:08 AM11:08 AM
172 - Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
11:16 AM11:16 AM
173 - Brain Gray and White Matter Alterations in Cognitive Long COVID
Lindsay S. McAlpine
Yale University, New Haven, CT, USA
11:24 AM11:24 AM
174 - Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV
Jacob Bolzenius
University of Missouri St Louis, St Louis, MO, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Cardiometabolic Complications and Aging: The Clock Is Ticking
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
175 - Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study
Alejandro Garcia
Hospital Ramón y Cajal, Madrid, Spain
10:13 AM10:13 AM
176 - Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study
Nila J. Dharan
University of New South Wales Sydney, Sydney, Australia
10:21 AM10:21 AM
177 - Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda
Mark J. Siedner
Massachusetts General Hospital, Boston, MA, USA
10:29 AM10:29 AM
178 - Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
179 - Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11:08 AM11:08 AM
180 - Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection
Patricia Martínez-Martín
La Paz University Hospital, Madrid, Spain
11:16 AM11:16 AM
181 - Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy
Michael J. Corley
Weill Cornell Medicine, New York, NY, USA
11:24 AM11:24 AM
182 - Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
Sara Gianella Weibel
University of California San Diego, La Jolla, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Gaps and Solutions in the HIV Response
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
183 - Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Steve Shoptaw
University of California Los Angeles, Los Angeles, CA, USA
10:13 AM10:13 AM
184 - Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda
Silas Odiya
Rakai Health Sciences Program, Kalisizo, Uganda
10:21 AM10:21 AM
185 - Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Kathryn L. Dovel
University of California Los Angeles, Los Angeles, CA, USA
10:29 AM10:29 AM
186 - Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study
Joseph G. Rosen
Brown University, Providence, RI, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
187 - How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?
Solis Winters
University of California Berkeley, Berkeley, CA, USA
11:08 AM11:08 AM
188 - Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia
Aaloke Mody
Washington University in St Louis, St Louis, MO, USA
11:16 AM11:16 AM
189 - Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV
Sarah Gimbel
University of Washington, Seattle, WA, USA
11:24 AM11:24 AM
190 - SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Expanding the Prevention Toolbox
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
191 - Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
10:13 AM10:13 AM
192 - ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
10:21 AM10:21 AM
193 - Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
194 - Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
195 - Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
11:08 AM11:08 AM
196 - PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Taimur Khan
Fenway Health, Boston, MA, USA
11:16 AM11:16 AM
197 - Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
11:32 AM11:32 AM
199 - An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR12
12:15 PMto1:15 PMPDT
12:00 PMto5:00 PMPDT
Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!
12:15 PM12:15 PM
(Introduction of Speakers)
12:15 PM12:15 PM
200 - Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results
Frederick G. Hayden
University of Virginia, Charlottesville, VA, USA
12:23 PM12:23 PM
201 - Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
Timothy Wilkin
University of California San Diego, La Jolla, CA, USA
12:31 PM12:31 PM
202 - Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
12:39 PM12:39 PM
203 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Babafemi Taiwo
ViiV Healthcare, Durham, NC, USA
12:47 PM12:47 PM
204A - Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1
Amy E. Colson
Community Resource Initiative, Boston, MA, USA
12:55 PM12:55 PM
204B - Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1
Chloe Orkin
Queen Mary University of London, London, UK
12:59 PM12:59 PM
Questions and Answers
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Hide and Seek: HIV in Tissues
1:30 PM1:30 PM
(Session Overview)
Zabrina L. Brumme
Simon Fraser University, Burnaby, Canada
1:35 PM1:35 PM
585 - HIV Reservoir in Jejunum Exhibit Distinct Phenotypic Features and Evoke Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
1:40 PM1:40 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
1:45 PM1:45 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
1:50 PM1:50 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
"Growing Up" With HIV Exposure
1:30 PM1:30 PM
(Session Overview)
Ceri Evans
University of Liverpool, Liverpool, United Kingdom
1:35 PM1:35 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
1:40 PM1:40 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
1:45 PM1:45 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
1:50 PM1:50 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Long COVID: Pathogenesis and Clinical Manifestations
1:30 PM1:30 PM
(Session Overview)
1:35 PM1:35 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:40 PM1:40 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
1:45 PM1:45 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:50 PM1:50 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
1:55 PM1:55 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Lessons in DoxyPEP Implementation
1:30 PM1:30 PM
(Session Overview)
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
1:35 PM1:35 PM
1275 - Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Jesús Santos
Hospital Universitario Virgen de la Victoria, Málaga, Spain
1:40 PM1:40 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
1:45 PM1:45 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Post-Exposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
1:50 PM1:50 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Pathogenesis of HIV in the Brain: The Final Frontier
4:00 PM4:00 PM
43 - Multiomics in the Brain
Howard Fox
University of Nebraska, Omaha, NE, USA
4:20 PM4:20 PM
44 - The Central Nervous System Reservoir: Impact for Cure and Ongoing Neuropathology
Melissa Churchill
Royal Melbourne Institute of Technology, Melbourne, Australia
4:40 PM4:40 PM
45 - Emerging Role of T Cells in the Central Nervous System
Lydie Trautmann
Henry M Jackson Foundation, Bethesda, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Making Sense of Integrase Strand Transfer Inhibitor Failure and Resistance
4:00 PM4:00 PM
46 - Dolutegravir Resistance: How Frequent Is It and How Will It Evolve?
Nicaise Ndembi
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
4:20 PM4:20 PM
47 - Dolutegravir Resistance: What Are the Implications for Antiretroviral Therapy Programs?
Jeremy Nel
University of Witwatersrand, Johannesburg, South Africa
4:40 PM4:40 PM
48 - Long-Acting InSTI Strategies: Understanding the Risks for Failure and Resistance
Saye Khoo
University of Liverpool, Liverpool, UK
5:00 PM5:00 PM
Panel Discussion
Brenda E. Crabtree Ramírez
National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Mexico
5:00 PM5:00 PM
Panel Discussion
Suzanne McCluskey
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Panel Discussion
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Putting People at the Center of Prevention: New Models of Delivery
4:00 PM4:00 PM
49 - Leveraging Private-Sector Pharmacies to Expand Reach of Biomedical HIV Prevention Interventions
Katrina Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
4:20 PM4:20 PM
50 - Empowering Communities: A Peer-Based Model for Expanding Equitable Access to PrEP and PEP in Mexico
Alaín Pinzón
Vihve Libre, Mexico City, Mexico
4:40 PM4:40 PM
51 - We’ll Come to You: A Mobile Clinic Preexposure Prophylaxis Delivery Model
Elzette Rousseau
Desmond Tutu HIV Foundation, Cape Town, South Africa
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 6
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
Previous:
MAR9
8:30 AMto12:30 PMPDT
12:00 PMto5:00 PMPDT
Scott M. Hammer Workshop for New Investigators and Trainees
8:30 AM8:30 AM
Welcome and (Session Overview) for the Scott M. Hammer Workshop for New Investigators and Trainees
8:31 AM8:31 AM
Virology: State of the Art and Navigating Presentations at CROI 2025
Stuart J.D. Neil
King's College London, London, UK
9:10 AM9:10 AM
Immunology: State of the Art and Navigating Presentations at CROI 2025
Lishomwa Ndhlovu
Weill Cornell Medicine, New York, NY, USA
10:10 AM10:10 AM
Prevention of HIV and STIs: State of the Art and Navigating Presentations at CROI 2025
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
10:50 AM10:50 AM
HIV Treatment and Complications of HIV Disease: State of the Art and Navigating Presentations at CROI 2025
Judith S. Currier
University of California Los Angeles, Los Angeles, CA, USA
11:50 AM11:50 AM
HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025
Joseph J. Eron, Jr
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
12:20 PM12:20 PM
Message to New Investigators
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Frontiers in Laboratory Technologies
2:00 PM2:00 PM
2 - Breaking the HIV Capsid: Atomic Force Microscopy Visualization
Juan R. Perilla
University of Delaware, Newark, DE, USA
2:30 PM2:30 PM
3 - Advances in Single-Cell Multiomic Profiling and Its Use in Virology and Immunology
Alexander Marson
University of California San Francisco, San Francisco, CA, USA
3:00 PM3:00 PM
4 - Visualizing Tissues: State-of-the-Art Single-Cell 3D Spatial Transcriptomics
Nikolaus Rajewsky
Berlin Institute for Medical Systems Biology, Berlin, Germany
3:30 PM3:30 PM
5 - Advances in CRISPR-Cas Editing Methods and Their Use in Virology and Immunology
Angela R. Wahl
University of Alabama at Birmingham, Birmingham, AL, USA
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Case-Based Workshop on the Liver and Its Complications
2:00 PM2:00 PM
6 - Liver Steatosis: New Nomenclature, New Tests, and New Drugs
Mandana Khalili
University of California San Francisco, San Francisco, CA, USA
2:40 PM2:40 PM
7 - Hepatitis B in the Gray Zone: Personalizing Treatment and Monitoring
Paul Y. Kwo
Stanford University, Stanford, CA, USA
3:20 PM3:20 PM
8 - Liver Cancer Surveillance: Who, How, When, and For How Long
Fasiha Kanwal
Baylor College of Medicine, Houston, TX, USA
3:50 PM3:50 PM
Discussion with Audience Questions and Answers
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Clinical Trial Design and Analysis
2:00 PM2:00 PM
9 - Using Machine Learning to Focus HIV Prevention Interventions
Carlos S. Saldana
Emory University, Atlanta, GA, USA
2:40 PM2:40 PM
10 - HIV Prevention Efficacy Trial Design: Lessons From Recent Trials
Holly Janes
Fred Hutchinson Cancer Center, Seattle, WA, USA
3:20 PM3:20 PM
11 - How Much Is Enough: The Importance of Pharmacokinetic Targets
Paolo Denti
University of Cape Town, Cape Town, South Africa
MAR9
2:00 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
Workshop on Antiretroviral Therapy: Case-Based Panel Discussion
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Jose R. Arribas
Hospital La Paz Institute for Health Research, Madrid, Spain
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, USA
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Cecilia Kanyama
UNC Project, Lilongwe. Malawi
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Juan Sierra-Madero
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico
2:01 PM2:01 PM
12 - Case Presentations With Panel Discussion, Plus Questions and Answers From the Audience
Oana Sandulescu
Carol Davila University of Medicine and Pharmacy, București, Romania
MAR9
5:00 PMto7:00 PMPDT
12:00 PMto5:00 PMPDT
Opening Session
5:00 PM5:00 PM
Welcome from the Conference Chair
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
5:10 PM5:10 PM
Introduction to the Bernard Fields Lecture
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, USA
5:15 PM5:15 PM
13 - Bernard Fields Lecture: How Integration Site Analyses Inform HIV Pathogenesis, Persistence, and Gene Therapy
Frederic D. Bushman
University of Pennsylvania, Philadelphia, PA, USA
5:40 PM5:40 PM
Introduction to the Martin Delaney Presentation
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
5:45 PM5:45 PM
14 - Martin Delaney Presentation: 40+ Years of HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must
Rebecca Denison
Woman Organized to Respond to Life-threatening Diseases (WORLD), Berkeley, CA, USA
6:10 PM6:10 PM
Introduction to the N'Galy-Mann Lecture
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
6:15 PM6:15 PM
15 - N'Galy-Mann Lecture: When Science Alone is Not Enough: The Intersection of Drug Use, Public Health, and Policy
Adeeba Kamarulzaman
Monash University Malaysia, Kuala Lumpur, Malaysia
6:40 PM6:40 PM
Special Presentation by the San Francisco Gay Men's Chorus
6:59 PM6:59 PM
Opening Session Conclusion and Welcome to the Opening Reception
Nicolas Chomont
Université de Montréal, Montreal, Canada
MAR9
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
MAR9
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
MAR10
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Monday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Monday
Diane V. Havlir
University of California San Francisco, San Francisco, CA, USA
8:35 AM8:35 AM
16 - HIV Cure: A Translational Research Perspective
Ole Søgaard
Aarhus University, Aarhus, Denmark
9:05 AM9:05 AM
17 - The Global HIV/AIDS Pandemic: Where Are We Now?
Chris Beyrer
Duke Global Health Institute, Durham, NC, USA
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Down But Not Out: Elite Control of HIV
1:30 PM1:30 PM
(Session Overview)
Javier Martinez-Pìcado
IrsiCaixa, Badalona, Spain
1:35 PM1:35 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
1:40 PM1:40 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:45 PM1:45 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
1:50 PM1:50 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
1:55 PM1:55 PM
494 - Loss of Virological Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Heart Failure: Hiding in Plain Sight
1:30 PM1:30 PM
(Session Overview)
Anoop Shah
London School of Hygiene & Tropical Medicine, London, UK
1:35 PM1:35 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
1:40 PM1:40 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally-Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
1:45 PM1:45 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
1:50 PM1:50 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:55 PM1:55 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
KS and KSHV: New Developments in Diagnosis, Therapy, and Pathogenesis
1:30 PM1:30 PM
(Session Overview)
Robert Yarchoan
National Institutes of Health, Bethesda, MD, USA
1:35 PM1:35 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
1:40 PM1:40 PM
792 - Impact of Low-Dose Intra-Lesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
1:45 PM1:45 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
1:50 PM1:50 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Hilda Muwando
Infectious Diseases Institute, Kampala, Uganda
1:55 PM1:55 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Meeting the Treatment and Prevention Needs of Transgender Women
1:30 PM1:30 PM
(Session Overview)
Tonia Poteat
Duke University, Durham, NC, USA
1:35 PM1:35 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
1:45 PM1:45 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
1:50 PM1:50 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
HIV Self-Testing: Here and Now
1:30 PM1:30 PM
(Session Overview)
Mateo Prochazka
World Health Organization, Geneva, Switzerland
1:40 PM1:40 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis and Treatment, 3/2023 - 5/2024
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
1:45 PM1:45 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Jen Hecht
1:50 PM1:50 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Deciphering the Mystery of Viral Rebound
4:00 PM4:00 PM
18 - Utilizing a Barcoded Virus Model to Identify the Source of Viral Rebound
Brandon Keele
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
4:20 PM4:20 PM
19 - Cellular and Tissue Sources of Viral Persistence and Rebound
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
4:40 PM4:40 PM
20 - Immune Responses During Viral Rebound
Rachel Rutishauser
University of California San Francisco, San Francisco, CA, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Filling the Gaps: Challenges and Opportunities in the Care of Children and Youth With Perinatal HIV
4:00 PM4:00 PM
21 - Advanced HIV Disease in Children
Pablo Rojo
Hospital Universitario 12 de Octubre, Madrid, Spain
4:20 PM4:20 PM
22 - HIV Care Continuum in Children
Irene Njuguna
University of Washington, Seattle, WA, USA
4:40 PM4:40 PM
23 - Sexual, Reproductive, and Pregnancy Health Among People With Perinatal HIV
Caroline Foster
Imperial College Healthcare NHS Trust, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Closing the Gaps in the HIV Response
4:00 PM4:00 PM
24 - Immediate Challenges and Long-Term Goals of the HIV Response
Jeffrey Imai-Eaton
Harvard TH Chan School of Public Health
4:20 PM4:20 PM
25 - Integration and Sustainability of the Global HIV Response
Tsitsi Apollo
Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe
4:40 PM4:40 PM
26 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind
Izukanji Sikazwe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 3 TestMiddleName 3 TestLastName 3
Institution 3
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 4 TestMiddleName 4 TestLastName 4
Institution 4
MAR10
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 4
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 2 TestMiddleName 2 TestLastName 2
Institution 2
MAR11
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
8:35 AM8:35 AM
27 - HIV Acquisition and Prevention During Pregnancy and Postpartum
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
9:05 AM9:05 AM
28 - Systems Vaccinology
Bali Pulendran
Stanford University, Stanford, CA, USA
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Natural-Born Killers
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Breaking In and Setting Up Home: From HIV Nuclear Entry and Integration to Viral Gene Expression and Establishing the Reservoir
4:00 PM4:00 PM
29 - How HIV Capsid Breaches the Nuclear Envelope Through Karyopherin Mimicry
David Jacques
University of New South Wales, Sydney, Australia
4:18 PM4:18 PM
30 - How HIV Integrates Into the Genome
Alan N Engelman
Dana–Farber Cancer Institute, Boston, MA, USA
4:36 PM4:36 PM
31 - Transcriptional and Epigenetic Regulation of HIV-1 Gene Expression
Melanie Ott
Gladstone Institutes, San Francisco, CA, USA
4:54 PM4:54 PM
32 - The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation
Mary Kearney
National Cancer Institute at Frederick, Frederick, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:00 PMPDT
12:00 PMto5:00 PMPDT
Hot Topic: Menopause and HIV
4:00 PM4:00 PM
33 - Beyond Hot Flashes: Women's Lived Experience of Menopause
Bridgette Picou
The Well Project: Women's Research Initiative on HIV/AIDS, Brooklyn, NY, USA
4:10 PM4:10 PM
34 - Clinical Management of Women With HIV in Menopause
Sara Looby
Massachusetts General Hospital, Boston, MA, USA
4:25 PM4:25 PM
35 - Influence of Hormone Changes on Physiology, Virology, and Immunology
Eileen Scully
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
5:00 PM5:00 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Long-Acting Preexposure Prophylaxis for HIV Prevention
4:00 PM4:00 PM
38 - Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention
Jonathan Li
Brigham and Women's Hospital, Boston, MA, USA
4:20 PM4:20 PM
39 - Complexities of HIV Diagnosis: What Lies Beneath
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
4:40 PM4:40 PM
40 - Long-Acting Preexposure Prophylaxis: Why Can’t We Get to Scale?
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
5:00 PMto6:00 PMPDT
12:00 PMto5:00 PMPDT
Tuberculosis: The Long Game
5:00 PM5:00 PM
36 - Long-Acting Treatments for Tuberculosis
Eric Nuermberger
The Johns Hopkins University, Baltimore, MD, USA
5:20 PM5:20 PM
37 - Post-Tuberculosis Disease: Opening Pandora's Box
Brian Allwood
Stellenbosch University, Cape Town, South Africa
6:00 PM6:00 PM
Discussion with Audience Questions and Answers
MAR11
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
MAR12
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Wednesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
41 - Long COVID: Causes, Consequences, and the Way Forward
Roger Paredes
IrsiCaixa, Badalona, Spain
9:05 AM9:05 AM
42 - Weight Gain in People With HIV
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
167 - Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection
Robert Paul
University of Missouri St Louis, St Louis, MO, USA
10:13 AM10:13 AM
168 - Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
10:21 AM10:21 AM
169 - Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART
Joshua C. Cyktor
University of Pittsburgh, Pittsburgh, PA, USA
10:29 AM10:29 AM
170 - Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART
Shelli Farhadian
Yale University, New Haven, CT, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
171 - Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
11:08 AM11:08 AM
172 - Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
11:16 AM11:16 AM
173 - Brain Gray and White Matter Alterations in Cognitive Long COVID
Lindsay S. McAlpine
Yale University, New Haven, CT, USA
11:24 AM11:24 AM
174 - Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV
Jacob Bolzenius
University of Missouri St Louis, St Louis, MO, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Cardiometabolic Complications and Aging: The Clock Is Ticking
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
175 - Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study
Alejandro Garcia
Hospital Ramón y Cajal, Madrid, Spain
10:13 AM10:13 AM
176 - Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study
Nila J. Dharan
University of New South Wales Sydney, Sydney, Australia
10:21 AM10:21 AM
177 - Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda
Mark J. Siedner
Massachusetts General Hospital, Boston, MA, USA
10:29 AM10:29 AM
178 - Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
179 - Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11:08 AM11:08 AM
180 - Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection
Patricia Martínez-Martín
La Paz University Hospital, Madrid, Spain
11:16 AM11:16 AM
181 - Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy
Michael J. Corley
Weill Cornell Medicine, New York, NY, USA
11:24 AM11:24 AM
182 - Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
Sara Gianella Weibel
University of California San Diego, La Jolla, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Gaps and Solutions in the HIV Response
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
183 - Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Steve Shoptaw
University of California Los Angeles, Los Angeles, CA, USA
10:13 AM10:13 AM
184 - Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda
Silas Odiya
Rakai Health Sciences Program, Kalisizo, Uganda
10:21 AM10:21 AM
185 - Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Kathryn L. Dovel
University of California Los Angeles, Los Angeles, CA, USA
10:29 AM10:29 AM
186 - Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study
Joseph G. Rosen
Brown University, Providence, RI, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
187 - How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?
Solis Winters
University of California Berkeley, Berkeley, CA, USA
11:08 AM11:08 AM
188 - Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia
Aaloke Mody
Washington University in St Louis, St Louis, MO, USA
11:16 AM11:16 AM
189 - Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV
Sarah Gimbel
University of Washington, Seattle, WA, USA
11:24 AM11:24 AM
190 - SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Expanding the Prevention Toolbox
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
191 - Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
10:13 AM10:13 AM
192 - ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
10:21 AM10:21 AM
193 - Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
194 - Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
195 - Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
11:08 AM11:08 AM
196 - PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Taimur Khan
Fenway Health, Boston, MA, USA
11:16 AM11:16 AM
197 - Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
11:32 AM11:32 AM
199 - An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR12
12:15 PMto1:15 PMPDT
12:00 PMto5:00 PMPDT
Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!
12:15 PM12:15 PM
(Introduction of Speakers)
12:15 PM12:15 PM
200 - Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results
Frederick G. Hayden
University of Virginia, Charlottesville, VA, USA
12:23 PM12:23 PM
201 - Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
Timothy Wilkin
University of California San Diego, La Jolla, CA, USA
12:31 PM12:31 PM
202 - Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
12:39 PM12:39 PM
203 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Babafemi Taiwo
ViiV Healthcare, Durham, NC, USA
12:47 PM12:47 PM
204A - Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1
Amy E. Colson
Community Resource Initiative, Boston, MA, USA
12:55 PM12:55 PM
204B - Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1
Chloe Orkin
Queen Mary University of London, London, UK
12:59 PM12:59 PM
Questions and Answers
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Hide and Seek: HIV in Tissues
1:30 PM1:30 PM
(Session Overview)
Zabrina L. Brumme
Simon Fraser University, Burnaby, Canada
1:35 PM1:35 PM
585 - HIV Reservoir in Jejunum Exhibit Distinct Phenotypic Features and Evoke Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
1:40 PM1:40 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
1:45 PM1:45 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
1:50 PM1:50 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
"Growing Up" With HIV Exposure
1:30 PM1:30 PM
(Session Overview)
Ceri Evans
University of Liverpool, Liverpool, United Kingdom
1:35 PM1:35 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
1:40 PM1:40 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
1:45 PM1:45 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
1:50 PM1:50 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Long COVID: Pathogenesis and Clinical Manifestations
1:30 PM1:30 PM
(Session Overview)
1:35 PM1:35 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:40 PM1:40 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
1:45 PM1:45 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:50 PM1:50 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
1:55 PM1:55 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR12
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Lessons in DoxyPEP Implementation
1:30 PM1:30 PM
(Session Overview)
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
1:35 PM1:35 PM
1275 - Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Jesús Santos
Hospital Universitario Virgen de la Victoria, Málaga, Spain
1:40 PM1:40 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
1:45 PM1:45 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Post-Exposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
1:50 PM1:50 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
1:55 PM1:55 PM
Discussion with Audience Q&A
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Pathogenesis of HIV in the Brain: The Final Frontier
4:00 PM4:00 PM
43 - Multiomics in the Brain
Howard Fox
University of Nebraska, Omaha, NE, USA
4:20 PM4:20 PM
44 - The Central Nervous System Reservoir: Impact for Cure and Ongoing Neuropathology
Melissa Churchill
Royal Melbourne Institute of Technology, Melbourne, Australia
4:40 PM4:40 PM
45 - Emerging Role of T Cells in the Central Nervous System
Lydie Trautmann
Henry M Jackson Foundation, Bethesda, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Making Sense of Integrase Strand Transfer Inhibitor Failure and Resistance
4:00 PM4:00 PM
46 - Dolutegravir Resistance: How Frequent Is It and How Will It Evolve?
Nicaise Ndembi
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
4:20 PM4:20 PM
47 - Dolutegravir Resistance: What Are the Implications for Antiretroviral Therapy Programs?
Jeremy Nel
University of Witwatersrand, Johannesburg, South Africa
4:40 PM4:40 PM
48 - Long-Acting InSTI Strategies: Understanding the Risks for Failure and Resistance
Saye Khoo
University of Liverpool, Liverpool, UK
5:00 PM5:00 PM
Panel Discussion
Brenda E. Crabtree Ramírez
National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Mexico
5:00 PM5:00 PM
Panel Discussion
Suzanne McCluskey
Massachusetts General Hospital, Boston, MA, USA
5:00 PM5:00 PM
Panel Discussion
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Putting People at the Center of Prevention: New Models of Delivery
4:00 PM4:00 PM
49 - Leveraging Private-Sector Pharmacies to Expand Reach of Biomedical HIV Prevention Interventions
Katrina Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
4:20 PM4:20 PM
50 - Empowering Communities: A Peer-Based Model for Expanding Equitable Access to PrEP and PEP in Mexico
Alaín Pinzón
Vihve Libre, Mexico City, Mexico
4:40 PM4:40 PM
51 - We’ll Come to You: A Mobile Clinic Preexposure Prophylaxis Delivery Model
Elzette Rousseau
Desmond Tutu HIV Foundation, Cape Town, South Africa
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR12
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 6
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
